Key result
Edoxaban was noninferior to warfarin for the prevention of stroke or systemic embolism, and reduced the risk of bleeding, major adverse cardiac events and cardiovascular death.
Why the study?
A large number of substudies, post hoc analyses, and observational studies have been published following the pivotal ENGAGE AF-TIMI 48 trial, prompting an updated review of evidence on edoxaban in AF patients.
Does edoxaban 60 mg once daily prevent stroke or systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
Does edoxaban 60 mg once daily prevent stroke or systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
Edoxaban 60 mg is an effective and safe alternative to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation across various clinical conditions.
Answers are grounded in this paper and cite their sources.
Supports edoxaban as cost-effective AF option; leaves open real-world economic validation in broader populations.
INTRODUCTION: Edoxaban is the last direct oral anticoagulant marketed for the prevention of stroke among patients with nonvalvular atrial fibrillation (AF). Areas covered: ENGAGE AF-TIMI 48 was the pivotal clinical trial that led to the approval of edoxaban 60 mg once daily. After the publication of this study, a great number of substudies and post hoc analyses have been published, together with some observational studies. The aim of this review was to update the current evidence about the use of edoxaban in AF patients. Expert opinion: In the ENGAGE AF-TIMI 48 trial, edoxaban 60 mg was noninferior to warfarin for the prevention of stroke or systemic embolism, but significantly reduced the risk of bleeding, major adverse cardiac events and death from cardiovascular causes. The relative efficacy and safety of edoxaban 60 mg compared with warfarin were independent of different clinical conditions, such as prior stroke, age, risk of falls, renal function, hepatic disease, ischemic heart disease, heart failure, valvular heart disease, or cancer. Data about the effectiveness and safety of edoxaban in real-life patients are scarce, but consistent with those of the pivotal clinical trial. Edoxaban seems a cost-effective alternative to warfarin among AF patients with moderate to high thromboembolic risk.
No takes yet. Share an insight, caveat, or question.
Escobar et al. (2019) conducted a review in nonvalvular atrial fibrillation. Edoxaban vs. warfarin was evaluated on stroke or systemic embolism. Edoxaban was noninferior to warfarin for the prevention of stroke or systemic embolism, and reduced the risk of bleeding, major adverse cardiac events and cardiovascular death.
Synapse has enriched 10 related papers. Consider them for comparative context: